ArticleMateria socio-medica2025
Reduction of Serum Interleukin-17 and Interleukin-23 Levels Following Narrow Band Ultraviolet B Treatment in Patients with Moderate-to-severe Psoriasis Vulgaris.
Article in Materia socio-medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Dynamics of Blood-Count-Derived Inflammatory Indices in the Course of Systemic Treatment for Psoriasis: A Single Center Study.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis, a common skin disorder, involves immune cells and cytokines in its pathogenesis. Narrow band ultraviolet B (NB-UVB) treatment has demonstrated efficacy and safety in managing this condition. Objective: This study aimed to assess changes in serum interleukin (IL)-17, IL-23, and tumor necrosis factor-alpha (TNF-α) levels during NB-UVB treatment for psoriasis vulgaris. Methods: An interventional, pre-post comparative study was conducted on patients with moderate to severe psoriasis vulgaris undergoing NB-UVB treatment. Patients were randomly allocated to Group 1 (n=39) receiving NB-UVB based on minimal erythema dose (MED) and Group 2 (n=32) based on Fitzpatrick skin type classification. Serum IL-17, IL-23, and TNF-α levels were measured before treatment and upon achieving PASI75. Results: There were no significant differences in serum IL-17, IL-23, and TNF-α levels between Group 1 and Group 2 at either time point. In Group 1, IL-17 levels decreased from median 2.6 pg/ml before treatment to 2.5 pg/ml at PASI75 (P=0.0107). In Group 2, IL-23 levels decreased from median 9.6 pg/ml pre-treatment to 1.3 pg/ml at PASI75 (P<0.0190). Across all patients, pre-treatment IL-17 and IL-23 levels (median 2.6 pg/ml and 7.1 pg/ml, respectively) were significantly higher compared to levels at PASI75 (P=0.0349 and P=0.0023, respectively). Conclusion: NB-UVB effectively treats moderate to severe psoriasis vulgaris, leading to reduced serum IL-17 and IL-23 levels irrespective of MED-based or skin type-based dosing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.